Equities Analysts Issue Forecasts for Omeros FY2025 Earnings

Omeros Co. (NASDAQ:OMER) – Analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Omeros in a note issued to investors on Monday, May 19th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings of ($2.04) per share for the year, up from their prior estimate of ($2.19). The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Several other equities research analysts have also commented on OMER. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Friday, May 16th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Monday. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Tuesday, May 13th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Down 5.5%

NASDAQ OMER opened at $3.11 on Wednesday. Omeros has a 52 week low of $2.97 and a 52 week high of $13.60. The firm has a market capitalization of $181.33 million, a P/E ratio of -1.35 and a beta of 2.42. The company has a 50-day moving average price of $6.77 and a 200-day moving average price of $8.09.

Institutional Investors Weigh In On Omeros

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. SG Americas Securities LLC increased its holdings in Omeros by 21.2% in the 4th quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 4,257 shares in the last quarter. Seros Financial LLC purchased a new stake in Omeros in the 4th quarter worth approximately $159,000. Stordahl Capital Management Inc. purchased a new stake in Omeros in the 4th quarter worth approximately $395,000. China Universal Asset Management Co. Ltd. purchased a new stake in Omeros in the 4th quarter worth approximately $121,000. Finally, New York State Common Retirement Fund increased its holdings in Omeros by 245.4% in the 4th quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 12,300 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.